Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass. -- Takeda ( TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist, in narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin-producing neurons in the brain. Orexin agonists are designed to address this underlying orexin deficiency. For the first time, this mechanism of action has been validated in Phase 3 studies demonstrating significant improvement across a broad range of symptoms. These results reinforce the potential of oveporexton to transform the standard of care. Read More
Recent Posts
Europe Faces Most Difficult Moment in Bid to Avoid Split With US
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Hastings Racecourse in Vancouver to shut down permanently, operator says
Russia’s Vital Oil Trade With India Is Down, But Not Out
Copper Quest Closes $1,927,000 Private Placement
This TSX stock was up 17% this week and it could gain another 36%, analysts say
AMC Entertainment Holdings, Inc. Transfers the Majority of its Equity Investment in Hycroft Mining Holding Corporation to Sprott Mining for a Net Consideration of $24.1 million
Guardian Capital Announces Estimated 2025 Annual Non-Cash Distributions for Guardian Capital ETFs
Emera Renews At-The-Market Equity Program
CRA warns of ‘aggressive tax schemes’ involving critical illness insurance
